Cargando…

Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis

Pembrolizumab is the standard for the first and second lines in treating metastatic urothelial carcinoma (UC). This systematic review and meta-analysis aimed to assess the value of pretreatment clinical characteristics and hematologic biomarkers for prognosticating response to pembrolizumab in patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Yanagisawa, Takafumi, Mori, Keiichiro, Katayama, Satoshi, Mostafaei, Hadi, Quhal, Fahad, Laukhtina, Ekaterina, Rajwa, Pawel, Motlagh, Reza Sari, Aydh, Abdulmajeed, König, Frederik, Grossmann, Nico C., Pradere, Benjamin, Miki, Jun, Kimura, Takahiro, Egawa, Shin, Shariat, Shahrokh F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732925/
https://www.ncbi.nlm.nih.gov/pubmed/34757531
http://dx.doi.org/10.1007/s10147-021-02061-0